Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg–Strauss)

  • Yann Nguyen
  • Loïc Guillevin
Part of the Rare Diseases of the Immune System book series (RDIS)


Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg–Strauss syndrome, a systemic necrotizing vasculitis of small- and medium-sized vessels, is characterized by asthma and blood eosinophilia, and anti-myeloperoxidase (MPO) anti-neutrophil cytoplasm antibodies (ANCA) in one-third of the patients. Its pathophysiology is complex, with several mechanisms being involved. EGPA typically occurs in previously asthmatic patients, and involves the skin, lungs, and peripheral nerves. Involvements of the heart, gastrointestinal tract, and/or kidney are severe, and associated with high mortality, as assessed by the Five-Factor Score (FFS). Overall survival has improved dramatically since corticosteroids and immunosuppressants have been prescribed, but relapses remain frequent. ANCA status seems to differentiate two groups with different clinical features and prognoses. All patients require corticosteroids, combined with an immunosuppressant (cyclophosphamide for induction and azathioprine for maintenance therapy) for those with severe/refractory disease and FFS-defined poor prognoses. Recent advances in EGPA management, including several novel immunomodulatory drugs and biotherapies, were or are being evaluated to improve EGPA patients’ prognoses.


Eosinophilic granulomatosis with polyangiitis Eosinophilia Systemic necrotizing vasculitis 


  1. 1.
    Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100.CrossRefGoogle Scholar
  3. 3.
    Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1):1–11.Google Scholar
  4. 4.
    Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture–recapture estimate. Arthritis Rheum. 2004;51(1):92–9.CrossRefGoogle Scholar
  5. 5.
    Sada K-E, Amano K, Uehara R, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) in Japan. Mod Rheumatol. 2014;24(4):640–4.CrossRefGoogle Scholar
  6. 6.
    Watts RA, Lane SE, Scott DG, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60(12):1156–7.Google Scholar
  7. 7.
    Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003;49(3):388–93.CrossRefGoogle Scholar
  8. 8.
    Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81.CrossRefGoogle Scholar
  9. 9.
    Iudici M, Puéchal X, Pagnoux C, et al. Brief report: childhood-onset systemic necrotizing vasculitides: long-term data from the French Vasculitis Study Group Registry. Arthritis Rheumatol. 2015;67(7):1959–65.CrossRefGoogle Scholar
  10. 10.
    Harrold LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM, et al. Incidence of Churg–Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol. 2005;32(6):1076–80.PubMedGoogle Scholar
  11. 11.
    Mouthon L, Khaled M, Cohen P, Guillevin L, Subra J. Systemic small sized vessel vasculitis after massive antigen inhalation. Ann Rheum Dis. 2001;60(9):903–4.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 1987;165(1):165–72.CrossRefGoogle Scholar
  13. 13.
    Bottero P, Bonini M, Vecchio F, et al. The common allergens in the Churg–Strauss syndrome. Allergy. 2007;62(11):1288–94.CrossRefGoogle Scholar
  14. 14.
    Franco J, Artés MJ. Pulmonary eosinophilia associated with montelukast. Thorax. 1999;54(6):558–60.CrossRefGoogle Scholar
  15. 15.
    Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg–Strauss syndrome: a case–crossover study. Thorax. 2008;63(8):677–82.CrossRefGoogle Scholar
  16. 16.
    Wechsler ME, Finn D, Gunawardena D, et al. Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708–13.CrossRefGoogle Scholar
  17. 17.
    Puéchal X, Rivereau P, Vinchon F. Churg–Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19(5):364–6.CrossRefGoogle Scholar
  18. 18.
    Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507–18.CrossRefGoogle Scholar
  19. 19.
    Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23.Google Scholar
  20. 20.
    Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg–Strauss syndrome. Arthritis Rheum. 2007;56(9):3159–66.CrossRefGoogle Scholar
  21. 21.
    Müschen M, Warskulat U, Perniok A, et al. Involvement of soluble CD95 in Churg–Strauss syndrome. Am J Pathol. 1999;155(3):915–25.CrossRefGoogle Scholar
  22. 22.
    Jakiela B, Szczeklik W, Sokolowska B, et al. Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg–Strauss syndrome. Rheumatology. 2009;48(10):1202–7.CrossRefGoogle Scholar
  23. 23.
    Terrier B, Bièche I, Maisonobe T, et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg–Strauss syndrome. Blood. 2010;116(22):4523–31.CrossRefGoogle Scholar
  24. 24.
    Tai PC, Holt ME, Denny P, Gibbs AR, Williams BD, Spry CJ. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg–Strauss syndrome. Br Med J (Clin Res Ed). 1984;289(6442):400–2.CrossRefGoogle Scholar
  25. 25.
    Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients. Rheumatology. 2012;51(10):1887–93.CrossRefGoogle Scholar
  26. 26.
    Jakiela B, Sanak M, Szczeklik W, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg–Strauss syndrome. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S23–34.Google Scholar
  27. 27.
    Stone JH, Merkel PA, Spiera R, et al. RAVE: rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.Google Scholar
  28. 28.
    Guillevin L, Pagnoux C, Karras A, et al. MAINRITSAN: rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80.CrossRefGoogle Scholar
  29. 29.
    Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol. 2013;33(5):965–76.CrossRefGoogle Scholar
  30. 30.
    Vaglio A, Strehl JD, Manger B, et al. IgG4 immune response in Churg–Strauss syndrome. Ann Rheum Dis. 2012;71(3):390–3.CrossRefGoogle Scholar
  31. 31.
    Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115–9.CrossRefGoogle Scholar
  32. 32.
    Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63.CrossRefGoogle Scholar
  33. 33.
    Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Eur Respir J. 2016;48(5):1429–41.CrossRefGoogle Scholar
  34. 34.
    Erzurum SC, Underwood GA, Hamilos DL, Waldron JA. Pleural effusion in Churg–Strauss syndrome. Chest. 1989;95(6):1357–9.CrossRefGoogle Scholar
  35. 35.
    Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. Thoracic manifestation of Churg–Strauss syndrome: radiologic and clinical findings. Chest. 2000;117(1):117–24.CrossRefGoogle Scholar
  36. 36.
    Herreman G, Ferme I, Puech H, Caubarrère I. Churg and Strauss’ allergic granulomatous angiitis with phrenic paralysis. 2 cases. Nouv Presse Med. 1980;9(47):3631.PubMedGoogle Scholar
  37. 37.
    Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27.CrossRefGoogle Scholar
  38. 38.
    Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.CrossRefGoogle Scholar
  39. 39.
    Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26–37.CrossRefGoogle Scholar
  40. 40.
    Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg–Strauss syndrome. Arthritis Rheum. 2010;62(2):627–34.Google Scholar
  41. 41.
    Dunogué B, Terrier B, Cohen P, et al. Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: a long-term retrospective study on 42 patients. Autoimmun Rev. 2015;14(9):774–80.CrossRefGoogle Scholar
  42. 42.
    Pugnet G, Gouya H, Puéchal X, et al. Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients. Rheumatolgy (Oxford). 2017;56(6):947–56.CrossRefGoogle Scholar
  43. 43.
    Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg–Strauss syndrome. Am J Kidney Dis. 2006;47(5):770–9.CrossRefGoogle Scholar
  44. 44.
    Azar N, Guillevin L, Lê Thi Huong D, Herreman G, Meyrier A, Godeau P. Symptomatic urogenital manifestations of polyarteritis nodosa and Churg–Strauss angiitis: analysis of 8 of 165 patients. J Urol. 1989;142(1):136–8.CrossRefGoogle Scholar
  45. 45.
    Takanashi T, Uchida S, Arita M, Okada M, Kashii S. Orbital inflammatory pseudotumor and ischemic vasculitis in Churg–Strauss syndrome: report of two cases and review of the literature. Ophthalmology. 2001;108(6):1129–33.CrossRefGoogle Scholar
  46. 46.
    Dietz A, Hübner C, Andrassy K. Makrolid-Antibiotika induzierte Vaskulitis (Churg–Strauss-Syndrom). Laryngol-Rhinol-Otologie (Stuttg). 1998;77(02):111–4.CrossRefGoogle Scholar
  47. 47.
    Yokoyama A, Kohno N, Fujino S, Inoue Y, Hiwada K. IgG and IgM rheumatoid factor levels parallel interleukin-6 during the vasculitic phase in a patient with Churg–Strauss syndrome. Intern Med Tokyo Jpn. 1995;34(7):646–8.CrossRefGoogle Scholar
  48. 48.
    Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore). 1984;63(2):65–81.CrossRefGoogle Scholar
  49. 49.
    Churg A. Recent advances in the diagnosis of Churg–Strauss syndrome. Mod Pathol. 2001;14(12):1284–93.CrossRefGoogle Scholar
  50. 50.
    Kahn J-E, Grandpeix-Guyodo C, Ackermann F, Charles P, Legrand F, Blétry O. Syndromes hyperéosinophiliques: actualités physiopathologiques et thérapeutiques. Rev Méd Intern. 2010;31(4):268–76.CrossRefGoogle Scholar
  51. 51.
    Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319–25.CrossRefGoogle Scholar
  52. 52.
    Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):389–413.CrossRefGoogle Scholar
  53. 53.
    Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53.Google Scholar
  54. 54.
    Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.CrossRefGoogle Scholar
  55. 55.
    Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med. 2005;143(9):632–8.CrossRefGoogle Scholar
  56. 56.
    Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg–Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–94.CrossRefGoogle Scholar
  57. 57.
    Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43(Suppl C):60–9.CrossRefGoogle Scholar
  58. 58.
    Puéchal X, Pagnoux C, Baron G, et al. CHUSPAN2: adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg–Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69(11):2175–86.CrossRefGoogle Scholar
  59. 59.
    Cohen P, Pagnoux C, Mahr A, et al. Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57(4):686–93.CrossRefGoogle Scholar
  60. 60.
    de Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80.CrossRefGoogle Scholar
  61. 61.
    Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955–60.CrossRefGoogle Scholar
  62. 62.
    Pagnoux C, Quéméneur T, Ninet J, et al. CORTAGE: treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117–27.CrossRefGoogle Scholar
  63. 63.
    Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.CrossRefGoogle Scholar
  64. 64.
    Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8.CrossRefGoogle Scholar
  65. 65.
    Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. Arthritis Rheum. 1995;38(11):1638–45.CrossRefGoogle Scholar
  66. 66.
    Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42(6):1149–53.CrossRefGoogle Scholar
  67. 67.
    Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397–402.CrossRefGoogle Scholar
  68. 68.
    Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology. 2008;47(7):1104–5.CrossRefGoogle Scholar
  69. 69.
    Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133.CrossRefGoogle Scholar
  70. 70.
    Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis. 2016;75(2):396–401.CrossRefGoogle Scholar
  71. 71.
    Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg–Strauss syndrome. Ann Rheum Dis. 2009;68(4):606.CrossRefGoogle Scholar
  72. 72.
    Danieli M, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis. 2004;63(12):1649–54.CrossRefGoogle Scholar
  73. 73.
    Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg–Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92(1):80–7.CrossRefGoogle Scholar
  74. 74.
    Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg–Strauss syndrome: a long-term observational study. Clin Exp Rheumatol. 2010;28(1) Suppl 57):24–30.Google Scholar
  75. 75.
    Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg–Strauss syndrome. Clin Exp Rheumatol. 2008;26(3) Suppl 49):S35–40.PubMedGoogle Scholar
  76. 76.
    Bargagli E, Rottoli P. Omalizumab treatment associated with Churg–Strauss vasculitis. Int Arch Allergy Immunol. 2008;145(3):268.CrossRefGoogle Scholar
  77. 77.
    Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53(2):201–6.CrossRefGoogle Scholar
  78. 78.
    Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg–Strauss): data from 17 patients. Arthritis Rheumatol. 2016;68(9):2274–82.Google Scholar
  79. 79.
    Kostianovsky A, Charles P, Alves J-F, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S83–9.Google Scholar
  80. 80.
    Herlyn K, Gross WL, Reinhold-Keller E. Longitudinale Effekte des strukturierten Patientenschulungsprogramms für Vaskulitispatienten. Z Für Rheumatol. 2008;67(3):206.CrossRefGoogle Scholar
  81. 81.
    Chumbley LC, Harrison EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg–Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. 1977;52(8):477–84.PubMedGoogle Scholar
  82. 82.
    Gaskin G, Clutterbuck EJ, Pusey CD. Renal disease in the Churg–Strauss syndrome. Diagnosis, management and outcome. Contrib Nephrol. 1991;94:58–65.CrossRefGoogle Scholar
  83. 83.
    Solans R, Bosch JA, Pérez-Bocanegra C, et al. Churg–Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford). 2001;40(7):763–71.Google Scholar
  84. 84.
    Durel C-A, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Arthritis Care Res. 2016;68(3):374–87.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Yann Nguyen
    • 1
  • Loïc Guillevin
    • 1
  1. 1.Department of Internal Medicine, Referral Center for Rare Systemic and Autoimmune Diseases, Hôpital Cochin, AP-HPUniversité Paris DescartesParisFrance

Personalised recommendations